-
41.
公开(公告)号:SG188878A1
公开(公告)日:2013-04-30
申请号:SG2013017603
申请日:2007-02-16
Applicant: ABBOTT LAB
Inventor: COWART MARLON D , ZHAO CHEN , SUN MINGHUA , BLACK LAWRENCE A , ZHENG GUO ZHU , GREGG ROBERT J , ZHANG GEOFF G Z , SHEIKH AHMAD Y , LOU XIAOCHUN , HENRY RODGER F , BARNES DAVID M , KOLACZKOWSKI LAWRENCE , HAIGHT ANTHONY R , CHANG SOU-JEN , WITTENBERGER STEVEN J , FICKES MICHAEL G
Abstract: Octahydro-pyrrolo[3,4-b]pyrrole derivatives are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Octahydro-pyrrolo[3,4-b]pyrrole compounds, methods for using such compounds, compositions for making them, and processes for preparing such compounds are disclosed herein.Figure 1
-
公开(公告)号:AU2013202002A1
公开(公告)日:2013-04-18
申请号:AU2013202002
申请日:2013-03-26
Applicant: ABBOTT LAB
Inventor: KRUEGER ALLAN C , GAO YI , KOTECKI BRIAN J , FLENTGE CHARLES A , MOTTER CHRISTOPHER E , MARING CLARENCE J , LIU DACHUN , BETEBENNER DAVID A , DEGOEY DAVID A , BARNES DAVID M , HUTCHINSON DOUGLAS K , ZHANG GEOFF G Z , HENGEVELD JOHN E , PRATT JOHN K , RANDOLPH JOHN T , SARRIS KATHY , STEWART KENT D , LONGENECKER KENTON L , TUFANO MICHAEL D , DONNER PAMELA L , HUANG PEGGY P , HENRY RODGER F , WAGNER ROLF , CHEN SHUANG , FRANCZYK II THADDEUS S , ROCKWAY TODD W , KATI WARREN M , LOU XIAOCHUN , LIU YAYA , HAIGHT ANTHONY R
IPC: C07D239/22 , A61K31/513 , A61P31/12 , C07D239/54 , C07D401/10 , C07D403/10 , C07D409/10 , C07D413/10 , C07D417/10
Abstract: URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C Present application relates to the compounds of formula I useful to treat hepatitis C (HCV) infections. In the structure of the disclosed compounds is the uracil or thymine derivative linked via a phenylene into either fused 2-ring cyclic system (R6) or alternatively via additional two atom linker (L) to a 5-6 membered monocycle (R6). Application further discloses polymorphs and pseudopolymorphs of two specific compounds: N-(6(3-t-butyl-5-(2>4-dioxo-3,4 dihydropyrimidin-1 (2H)- y!)2-methoxy-phenyl)naphthalen-2-yl)methanesulfonamide and (E) N-(4(3-t-butyl-5-(2,4-dioxo-3)4-dihydropyrimidin-1(2H)-yl)2-methoxy-styryl phenyl)methanesulfonamide.
-
公开(公告)号:CO6470833A2
公开(公告)日:2012-06-29
申请号:CO11162226
申请日:2011-11-25
Applicant: ABBOTT LAB
Inventor: CATRON NATHANIEL , FICKES MICHAEL G , HAIGHT ANTHONY R , HEEMSTRA KATHERINE , SANZGIRI YESHWANT , SCHMITT ERIC A , TONG PING , ZHANG GEOFF , FISCHER CRISTINA , ZHOU DELIANG
Abstract: Una composición farmacéutica que se puede suministrar en forma oral, que comprende a un compuesto inhibidor de las proteínas de la familia Bcl-2, por ejemplo, ABT-263, un antioxidante calcógeno más pesado y un vehículo lípido sustancialmente no acuoso, donde dicho compuesto y dicho antioxidante están formando una solución en el vehículo. La composición es apropiada para administrar por vía oral a un sujeto que la necesita para tratar una enfermedad caracterizada por la sobreexpresión de una o más proteínas antiapoptóticas de la familia Bcl-2 por ejemplo cáncer.
-
公开(公告)号:SG175145A1
公开(公告)日:2011-11-28
申请号:SG2011073624
申请日:2010-04-30
Applicant: ABBOTT LAB
Inventor: CATRON NATHANIEL , FICKES MICHAEL , FISCHER CRISTINA , HAIGHT ANTHONY R , HEEMSTRA KATHERINE , SANZGIRI YESHWANT , SCHMITT ERIC , TONG PING , ZHANG GEOFF , ZHOU DELIANG
Abstract: An orally deliverable pharmaceutical composition comprises a Bcl-2 family protein inhibitory compound, e.g., ABT-263, a heavier-chalcogen antioxidant and a substantially non-aqueous lipid carrier, wherein said compound and said antioxidant are in solution in the carrier. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
-
公开(公告)号:AU2010242925A1
公开(公告)日:2011-11-10
申请号:AU2010242925
申请日:2010-04-30
Applicant: ABBOTT LAB
Inventor: PAUL DAVID , MICHAEL FICKES , CRISTINA FISCHER , HAIGHT ANTHONY R , KATHERINE HEEMSTRA , KENNAN MARSH , PETER MAYER , VITALY RUBIN , YESHWANT SANZGIRI , ERIC SCHMITT , PING TONG , DELIANG ZHOU
Abstract: An orally deliverable pharmaceutical composition comprises a drug-carrier system having a Bcl-2 family protein inhibitory compound, ., ABT-263, in solution in a substantially non-aqueous carrier that comprises at least one phospholipid and a pharmaceutically acceptable solubilizing agent. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
-
公开(公告)号:PT2203431E
公开(公告)日:2011-10-12
申请号:PT08832330
申请日:2008-09-17
Applicant: ABBOTT LAB
Inventor: HAIGHT ANTHONY R , KATI WARREN M , KRUEGER ALLAN C , STEWART KENT D , PRATT JOHN K , HENGEVELD JOHN E , BETEBENNER DAVID A , DONNER PAMELA L , MARING CLARENCE J , RANDOLPH JOHN T , HUTCHINSON DOUGLAS K , LIU DACHUN , LIU YAYA , LONGENECKER KENTON L , ROCKWAY TODD W , WAGNER ROLF , BARNES DAVID M , CHEN SHUANG , GAO YI , KOTECKI BRIAN J , LOU XIAOCHUN , ZHANG GEOFF G Z , FLENTGE CHARLES A , DEGOEY DAVID A , MOTTER CHRISTOPHER E , FRANCZYK THADDEUS S II
IPC: C07D239/22 , A61K31/513 , A61P31/12 , C07D239/54 , C07D401/10 , C07D403/10 , C07D405/10 , C07D409/10 , C07D413/10 , C07D417/10
-
47.
公开(公告)号:SG170033A1
公开(公告)日:2011-04-29
申请号:SG2011013430
申请日:2007-02-16
Applicant: ABBOTT LAB
Inventor: COWART MARLON D , ZHAO CHEN , SUN MINGHUA , BLACK LAWRENCE A , ZHENG GUO ZHU , GREGG ROBERT J , ZHANG GEOFF G Z , SHEIKH AHMAD Y , LOU XIAOCHUN , HENRY RODGER F , BARNES DAVID M , KOLACZKOWSKI LAWRENCE , HAIGHT ANTHONY R , CHANG SOU-JEN , WITTENBERGER STEVEN J , FICKES MICHAEL G
Abstract: OCTAHYDRO-PYRROLO[3,4-B] PYRROLE DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTOR LIGANDS Octahydro-pyrrolo[3,4-b]pyrrole derivatives are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Octahydro-pyrrolo[3,4-b]pyrrole compounds, methods for using such compounds, compositions for making them, and processes for preparing such compounds are disclosed herein.
-
公开(公告)号:CA2750125A1
公开(公告)日:2010-08-19
申请号:CA2750125
申请日:2010-02-09
Applicant: ABBOTT LAB
Inventor: SHEKHAR SHASHANK , YU SU , HAIGHT ANTHONY R , CHMURA PRESTON E , KISHORE VIMAL
IPC: A61K31/135
Abstract: Disclosed herein are methods of making compounds which are agonists or antagonists of one or more of the individual receptors of the S1P receptor family.
-
公开(公告)号:MX2010002904A
公开(公告)日:2010-06-02
申请号:MX2010002904
申请日:2008-09-17
Applicant: ABBOTT LAB
Inventor: BARNES DAVID M , PRATT JOHN K , BETEBENNER DAVID A , MARING CLARENCE J , WAGNER ROLF , RANDOLPH JOHN T , HUTCHINSON DOUGLAS K , KRUEGER ALLAN C , HENRY RODGER F , KOTECKI BRIAN J , HAIGHT ANTHONY R , GAO YI , STEWART KENT D , LONGENECKER KENTON L , ROCKWAY TODD W , LIU DACHUN , LOU XIAOCHUN , CHEN SHUANG , ZHANG GEOFF G Z , LIU YAYA , FRANCZYK THADDEUS S II , HENGEVELD JOHN E , DONNER PAMELA R
IPC: C07D239/22 , A61K31/506 , A61K31/513 , A61P31/14 , C07D239/54 , C07D239/553 , C07D401/10 , C07D403/10 , C07D405/10 , C07D409/10 , C07D413/10
Abstract: Esta invención se relaciona con: (a) compuestos y sales de los mismos que, entre otros, inhiben el HCV; (b) intermediarios de utilidad para la preparación de dichos compuestos y sales; (c) composiciones que comprenden dichos compuestos y sales; (d) métodos para preparar dichos intermediarios, compuestos, sales y composiciones; (e) métodos de uso de dichos compuestos, sales y composiciones; y (f) conjuntos de elementos que comprenden dichos compuestos, sales y composiciones. Los compuestos son útiles en el tratamiento de hepatitis C y tienen la siguiente estructura general: Formula (1).
-
公开(公告)号:MX2010002902A
公开(公告)日:2010-06-02
申请号:MX2010002902
申请日:2008-09-17
Applicant: ABBOTT LAB
Inventor: BARNES DAVID M , PRATT JOHN K , BETEBENNER DAVID A , DONNER PAMELA L , MARING CLARENCE J , WAGNER ROLF , RANDOLPH JOHN T , DEGOEY DAVID A , FLENTGE CHARLES A , HUTCHINSON DOUGLAS K , KRUEGER ALLAN C , KOTECKI BRIAN J , HAIGHT ANTHONY R , GAO YI , STEWART KENT D , LONGENECKER KENTON L , ROCKWAY TODD W , MOTTER CHRISTOPHER E , LIU DACHUN , ZHANG GEOFF G Z , LOU XIAOCHUN , CHEN SHUANG , KATI WARREN M , LIU YAYA , FRANCZYK THADDEUS S II , HENGEVELD JOHN E
IPC: C07D239/22 , A61K31/513 , A61P31/12 , C07D239/54 , C07D401/10 , C07D403/10 , C07D405/10 , C07D409/10 , C07D413/10 , C07D417/10
Abstract: Esta invención se relaciona con: (a) compuestos y sales de los mismos que, entre otros, inhiben el HCV; (b) intermediarios de utilidad para la preparación de dichos compuestos y sales; (c) composiciones que comprenden dichos compuestos y sales; (d) métodos para preparar dichos intermediarios, compuestos, sales y composiciones; (e) métodos de uso de dichos compuestos, sales y composiciones; y (f) conjuntos de elementos que comprenden dichos compuestos, sales y composiciones.
-
-
-
-
-
-
-
-
-